PDGFRA and gastrointestinal stromal tumor: Among 28 patients with PDGFRA D842V-mutant GIST receiving a starting dose of 300 mg, partial response (PR) was achieved in 21 patients as measured by IRRC assessment, resulting in an ORR of 75% (95% CI: 55%–89%) (Table 5).